Please login to the form below

Not currently logged in

Chiltern promotes Aize Smink and Linda Christmas

CRO makes changes as new CEO Dr Jim Esinhart takes office

Chiltern chief operating officer Aize SminkUK-based CRO Chiltern has made two senior appointments, promoting Aize Smink to chief operating officer and Linda Christmas to chief resourcing officer.

Smink was formerly senior executive VP of global clinical development and in his new role working out of Brussels will provide leadership and oversight of Chiltern's global clinical development and global scientific services divisions.

He has more than 20 years of development experience, spanning pharma, biotech and medical devices, and has been with Chiltern since 2006.

Meanwhile, Linda Christmas steps up from senior executive VP of global resourcing solutions in a promotion that Chiltern said recognises the role she has played as the head of its global resourcing division.

She has been with Chiltern since 1997 and has more than 25 years of clinical research experience.

The company makes the executive changes as its new CEO Dr Jim Esinhart takes office.

Commenting on the two promotions he said: “Aize and Linda are talented and experienced industry leaders. These appointments build on their strengths, as well as the strengths of our global team.

“As a leading mid-tier CRO, we believe the integration of services, technology and optimal resourcing are critical for success. I look forward to working closely with Aize and Linda in their new roles as we continue Chiltern's long-standing track record of delivering high quality and responsive services.”

6th November 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge